Patents Assigned to UNIVERSITE ' CLAUDE BERNARD DE LYON 1
-
Patent number: 9120856Abstract: The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and low level of sialic acid, high ADCC function and no CDC. The present invention also relates to the use of these antibodies in the treatment, prevention or management of diseases or disorders, such as cancer, especially a B-cell malignancy and auto-immune disease.Type: GrantFiled: July 18, 2011Date of Patent: September 1, 2015Assignees: INTERNATIONAL-DRUG-DEVELOPMENT BIOTECH, UCBL UNIVERSITE CLAUDE BERNARD DE LYON 1, HOSPICES CIVILS DE LYONInventors: Gilles Salles, Claudine Vermot-Desroches
-
Patent number: 8926988Abstract: The present application concerns mutant proteins of the fusion protein (F protein) of the parainfluenza virus (PIV) which are currently indexed as type 5 PIV (PIV-5 or PIV5) and type 2 PIV (PIV-2 or PIV2). The present application concerns products deriving therefrom, such as: nucleic acids, vectors, cells, fusion inhibitors of the antibody, aptamer, interfering RNA type; myelomas, hybridomas; stem and progenitor cells. The present application also concerns mutant proteins and products derived therefrom for use in medical and biotechnological applications.Type: GrantFiled: November 17, 2009Date of Patent: January 6, 2015Assignees: Centre National de la Recherche Scientifique, Universite Claude Bernard de Lyon 1, Les Hospices Civils de LyonInventors: Manuel Melchior Jean-Pierre Rosa Calatrava, Olivier Terrier, Francois Edouard Julien Durupt
-
Patent number: 8906386Abstract: The present application concerns mutant proteins of the fusion protein (F protein) of the parainfluenza virus (PIV) which are currently indexed as type 5 PIV (PIV-5 or PIV5) and type 2 PIV (PIV-2 or PIV2). The present application concerns products deriving therefrom, such as: nucleic acids, vectors, cells, fusion inhibitors of the antibody, aptamer, interfering RNA type; myelomas, hybridomas; stem and progenitor cells. The present application also concerns mutant proteins and products derived therefrom for use in medical and biotechnological applications.Type: GrantFiled: November 17, 2009Date of Patent: December 9, 2014Assignees: Centre National de la Recherche Scientifique, Universite Claude Bernard de Lyon 1, Les Hospices Civils de LyonInventors: Manuel Melchior Jean-Pierre Rosa Calatrava, Olivier Terrier, Francois Edouard Julien Durupt
-
Patent number: 8895744Abstract: The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in the description, to their pharmaceutical compositions and use thereof for the treatment of cancer expressing oncogenic ALK protein, particularly anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), inflammatory myofibroblastic tumors (IMT) and non-small cell lung cancer (NSCLC).Type: GrantFiled: August 27, 2009Date of Patent: November 25, 2014Assignees: Universita' Degli Studi di Milano-Bicocca, Universite' de Geneve, Universite' Claude Bernard de Lyon 1Inventors: Carlo Gambacorti Passerini, Luca Mologni, Leonardo Scapozza, Shaheen Ahmed, Peter G. Goekjian, David Gueyrard, Florence Popowycz, Benoit Joseph, Cedric Schneider, Pierre Garcia
-
Publication number: 20130183306Abstract: The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and low level of sialic acid, high ADCC function and no CDC. The present invention also relates to the use of these antibodies in the treatment, prevention or management of diseases or disorders, such as cancer, especially a B-cell malignancy and auto-immune disease.Type: ApplicationFiled: July 18, 2011Publication date: July 18, 2013Applicants: INTERNATIONAL - DRUG - DEVELOPMENT - BIOTECH, HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD DE LYON 1Inventors: Gilles Salles, Claudine Vermot-Desroches
-
Patent number: 8481691Abstract: The present invention relates to a method for selectively extracting membrane proteins using at least one calixarene of formula (I). The use of calixarenes in the method according to the invention enables the selective solubilization of the membrane proteins while preserving the three-dimensional structure that is essential to the enzymatic activity thereof.Type: GrantFiled: May 28, 2009Date of Patent: July 9, 2013Assignees: Centre National de la Recherche Scientifique—CNRS, Universite Claude Bernard de Lyon 1Inventors: Anthony W. Coleman, Cyrille Mbemba, Pierre Falson, Rima Matar, Frederic Huche
-
Publication number: 20110318355Abstract: The present application concerns mutant proteins of the fusion protein (F protein) of the parainfluenza virus (PIV) which are currently indexed as type 5 PIV (PIV-5 or PIV5) and type 2 PIV (PIV-2 or PIV2). The present application concerns products deriving therefrom, such as: nucleic acids, vectors, cells, fusion inhibitors of the antibody, aptamer, interfering RNA type; myelomas, hybridomas; stem and progenitor cells. The present application also concerns mutant proteins and products derived therefrom for use in medical and biotechnological applications.Type: ApplicationFiled: November 17, 2009Publication date: December 29, 2011Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, LES HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD DE LYON 1Inventors: Manuel Melchior Jean-Pierre Rosa Calatrava, Olivier Terrier, Francois Edouard Julien Durupt
-
Publication number: 20110311541Abstract: The present application concerns mutant proteins of the fusion protein (F protein) of the parainfluenza virus (PIV) which are currently indexed as type 5 PIV (PIV-5 or PIV5) and type 2 PIV (PIV-2 or PIV2). The present application concerns products deriving therefrom, such as: nucleic acids, vectors, cells, fusion inhibitors of the antibody, aptamer, interfering RNA type; myelomas, hybridomas; stem and progenitor cells. The present application also concerns mutant proteins and products derived therefrom for use in medical and biotechnological applications.Type: ApplicationFiled: November 17, 2009Publication date: December 22, 2011Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, LES HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD DE LYON 1Inventors: Manuel Melchior Jean-Pierre Rosa Calatrava, Olivier Terrier, Francois Edouard Julien Durupt
-
Publication number: 20110281862Abstract: The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in the description, to their pharmaceutical compositions and use thereof for the treatment of cancer expressing oncogenic ALK protein, particularly anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), inflammatory myofibroblastic tumours (IMT) and non-small cell lung cancer (NSCLC).Type: ApplicationFiled: August 27, 2009Publication date: November 17, 2011Applicants: Universita' Degli Studi di Milano - Bicocca, Universite' Claude Bernard de Lyon 1, Universite' de GeneveInventors: Carlo Gambacorti Passerini, Luca Mologni, Leonardo Scapozza, Shaheen Ahmed, Peter G. Goekjian, David Gueyrard, Florence Popowycz, Benoit Joseph, Cedric Schneider, Pierre Garcia
-
Patent number: 7982063Abstract: The invention relates to a composite material comprising nanoparticles of at least one metal derivative and at least one type of carboxylic and/or sulfonic acid derivative organic compound chemically bound in a covalent manner with said nanoparticles by means of at least one carboxylic and/or sulfonic function.Type: GrantFiled: August 4, 2006Date of Patent: July 19, 2011Assignees: Centre National de la Recherche Scientifique (C.N.R.S.), UCBL Universite Claude Bernard de Lyon 1Inventors: Liliane Georgette Hubert-Pfalzgraf, Eugène Hubert, legal representative, Stephane Daniele
-
Publication number: 20110144314Abstract: The present invention relates to a method for selectively extracting membrane proteins using at least one calixarene of formula (I). The use of calixarenes in the method according to the invention enables the selective solubilization of the membrane proteins while preserving the three-dimensional structure that is essential to the enzymatic activity thereof.Type: ApplicationFiled: May 28, 2009Publication date: June 16, 2011Applicants: Centre National De La Recherche Scientifique CNRS, Universite Claude Bernard De Lyon 1Inventors: Anthony William Coleman, Cyrille Mbemba, Pierre Falson, Rima Matar, Frédéric Huché
-
Publication number: 20110112110Abstract: Inhibitors of the oncogenic tyrosine kinase ALK and of the Bcr-Abl mutant T315I Bcr-Abl, pharmaceutical compositions containing the same and their use for the treatment of hyper-proliferative diseases.Type: ApplicationFiled: March 30, 2009Publication date: May 12, 2011Applicants: UNIVERSITA' DEGLISTUDI DI MILANO- BICOCCA, UNIVERSITE ' DE GENEVE, UNIVERSITE ' CLAUDE BERNARD DE LYON 1Inventors: Carlo Gambacorti Passerini, Rosalind Helen Gunby, Alfonso Zambon, Leonardo Scapozza, Shaheen Ahmed, Peter G. Goekjian, David Gueyrard, Florence Popowycz, Cerric Schneider
-
Publication number: 20100121088Abstract: The invention relates to a composite material comprising nanoparticles of at least one metal derivative and at least one type of carboxylic and/or sulfonic acid derivative organic compound chemically bound in a covalent manner with said nanoparticles by means of at least one carboxylic and/or sulfonic function.Type: ApplicationFiled: August 4, 2006Publication date: May 13, 2010Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), UCBL UNIVERSITE CLAUDE BERNARD DE LYON1Inventors: Liliane Georgette Hubert-Pfalzgraf, Eugène Hubert, Stephane Daniele
-
Publication number: 20090104135Abstract: The invention relates to the use of composite material which comprises nanoparticles of a least one metal derivative and at least one organic sunscreen agent which is chemically bound with said particles in a covalent manner in the form of an ultraviolet radiation protective agent containing the inventive composite material. Cosmetic ultraviolet radiation protective compositions comprises said mixture are also disclosed.Type: ApplicationFiled: August 4, 2006Publication date: April 23, 2009Applicants: LVMH RECHERCHE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UCBL UNIVERSITE CLAUDE BERNARD DE LYON 1Inventors: Stephane Daniele, Veronique Guyot-Ferreol, Jean-Francois Tranchant, Eugene Hubert, Caroline Hubert